Diabetic retinopathy (DR) is the most common microvascular complication of diabetes and 3 the leading cause of visual impairment in working-age adults. Diabetic patients often 4 develop DR despite appropriate control of systemic risk factors, suggesting the involvement 5 of other pathogenic factors. We hypothesize a plasma metabolic signature of DR that is 6 distinct and resolvable from that of diabetes alone. A nested population-based case-control 7 metabonomic study was first performed on 40 DR cases and 40 diabetic controls using gas 8 chromatography-mass spectrometry. Eleven metabolites were found to be correlated with 9 DR, and the majority were robust when adjusted for metabolic risk factors and confounding 10 kidney disease. The metabolite markers 2-deoxyribonic acid; 3,4-dihydroxybutyric acid; 11 erythritol; gluconic acid and ribose were validated in an independent sample set with 40 DR 12 cases, 40 diabetic controls and 40 non-diabetic individuals. DR cases and diabetic controls 13 were matched by HbA1c in the validation set. Activation of the pentose phosphate pathway 14 was identified from the list of DR metabolite markers. 
of DR in the vitreous humour (24) . However, the invasive nature of vitreous sampling limits 1 study replication and the translational potential of any biomarkers identified from vitreous 2 fluid. In contrast, plasma or sera have remained the biofluid of choice in metabonomic 3 studies. With these biological matrices, several research groups have reported metabolite 4 markers of global (25; 26) and targeted (27-29) metabonomic analysis. These studies 5 however, did not account for confounders and co-morbidities, such as medication use and 6 kidney disease. This study's objective is to investigate if the plasma metabotype of DR is 7 resolvable from the metabolic perturbations associated with underlying diabetes, and to 8 identify novel metabolite markers of DR. 9 
10

Research Design and Methods
12
Sample Selection
13
We first conducted a nested population-based case-control study on 40 diabetes patients 14 with DR and 40 diabetes patients without DR (discovery set) selected from banked plasma 15 collected as part of the Singapore Indian Eye Study (30). Metabolite markers of DR identified 16 from the discovery set were separately quantified in a separate sample set with 40 diabetes 17 patients with DR, 40 diabetes patients without DR and 40 participants with no diabetes 18 (validation set). 19 
20
For the discovery set, cases were 40 participants with type 2 diabetes with moderate non-21 proliferative DR (level 43 on the ETDRS scale) or worse in at least one eye, documented from 22 retinal photographs (31). Equal numbers of samples were selected from participants who 23 had been diagnosed with diabetes for ten years or less, and for over ten years. Controls 24 were 40 participants with diabetes who had no DR, matched to cases by diabetes duration 25 (in 5 year bands). 26
27
For the validation set, participants with chronic kidney disease were excluded from selection. 28
Cases were 40 participants with type 2 diabetes with moderate non-proliferative DR (level 29 43 on the ETDRS scale) or worse in at least one eye. Controls were 40 participants with 30 diabetes who had no DR, matched to cases by HbA1c levels (in 0.5% bands), age (in 5 yearµL of methanol were added to each sample. Samples were mixed for 15 min at room 1 temperature and centrifuged for 10 min at 16,000 g (4°C). The top 300 µL of each 2 supernatant was transferred to a glass tube and dried under nitrogen gas. The dried samples 3 were re-suspended in 100 µL of toluene, vortexed vigorously for 10 s and dried again under 4 nitrogen. A two-step derivatization method was employed for chemical derivatisation of 5 metabolites. Samples were first incubated with 50 µL of 2 % methoxyamine chloride in 6 pyridine (Pierce Biotechnology) for 1.5 h at 60 °C. Next, 50 µL of N-methyl-N-7 trifluoroacetamide (Thermo Scientific) was added and the samples were incubated again for 8 1 h at 60 °C. 80 µL of derivatised samples were transferred to silanised glass vials for gas 9 chromatography-mass spectrometry (GC-MS) analysis. Ten aliquots of pooled K 2 EDTA 10 human plasma (Innovative Research Inc., batch 052511), three aliquots of distilled water 11 and 10 mM glucose in distilled water were also similarly prepared. Two pooled plasma 12 samples were injected before the first study sample and one pooled plasma sample was 13 injected after every ten study samples to act as quality controls (QC). The blanks and glucose 14 standards were injected at the beginning, at the middle and at the end of the sample batch. 15 16 GC-MS analysis was performed using an Agilent 6890N gas chromatograph (Agilent 17
Technologies) coupled to a LECO Pegasus III (4D) GC × GC/MS time-of-flight mass analyzer 18 operating in GC/MS mode (Leco Corporation). Sample injection was performed by a CTC PAL 19 autosampler (CTC Analytics AG). The injection temperature was 250 °C and injection volume 20 was set to 1 µL, with a spilt ratio of 1:2. A capillary column with DB-1 stationary phase of 21 21.5 m × 0.25 mm, 0.25 µm film thickness (Agilent Technologies) was used with a constant 22 helium carrier gas flow of 1.5 mL/min. The temperature gradient was held at 70 °C for 2 min, 23 increased at a rate of 10 °C/min to 310 °C, and held at 310 °C for 6 min. The transfer line and 24 ion source were set at 280 and 250 °C respectively. Mass spectra were acquired after a 25 delay of 240 s post-injection, from m/z 45 to 600 at 20 Hz using ionization energy of 70 eV 26 and a detector voltage of 1650 V. 27
28
Data Processing
29
Deconvolution and peak finding were performed with ChromaTOF (version 4.44, Leco2.5 s and (iii) a minimum of two apexing masses. Instrument performance was assessed 1 using the peak area of D-27 myristic acid, the internal standard. 2 3 Peak alignment was performed with the "calibration" function in ChromaTOF (33). A 4 reference table was first built using data obtained from plasma samples of participants who 5 had declared no medication usage. There were three such participants among the selected 6 samples. Samples from an additional six diabetic participants were who had declared no 7 medication usage were analysed for the purpose of building the reference table. Each peak 8 was only included in the reference table if (i) it was detected in at least seven out of nine 9 medication-free samples (78%) and (ii) its average integrated peak area was at least five 10 times greater than that of the glucose standards and blanks. This ensured that the peaks in 11 the reference table included endogenous metabolites as represented in the medication-free 12 samples and excluded xenobiotics such as drugs and their associated metabolites. Peaks 13 derived from glucose were saturated in most samples and were thus excluded from the 14 reference table. Furthermore, plasma glucose levels in the DR group were not significantly 15 different from diabetic controls in this study. 16
17
Peak data from DR patients and diabetic controls were then aligned to the reference table 18 using a retention time tolerance of 3 s. Retention times were converted to Kovats retention 19 indices using C8-C40 alkane standards (Sigma Aldrich). Peaks with missing values in more 20 than 20% of the samples were discarded. For peaks with missing values in less than 20% of 21 the samples, the missing values were filled with half of the lowest detected peak area. The 22 raw peak areas was normalised to the sum of peak areas within the 90 th percentile of peak 23 area distribution in each sample, using the median sample as the denominator in the 24 calculation of normalisation factors. Normalised data was then log transformed (base 2). 25
Peaks with coefficient of variation (CV) greater than 30% in the QC samples were not 26 considered for further analysis. 27
28
Statistical Analysis
29
Principal component analysis (PCA) with unit variance scaling was performed to evaluate the 30 presence of dominating trends in the peak data. Mann-Whitney U tests were firstfalse discovery rates (FDR) was calculated using q-values (34). Metabolites were considered 1 significant if their q-values were less than or equal to 0.2, and if their fold-changes were 2 greater than 1.2 or less than 0.8. The area under the curve (AUC) in receiver operating 3 characteristic (ROC) analysis was calculated to evaluate the discriminating power of the 4 metabolite markers (35). Logistic regression models were fit to evaluate the association of 5 metabolite peak areas with the presence of DR. Odds ratios with 95% confidence intervals 6 (CI) were calculated based on one standard deviation change in metabolite peak areas. 7
Clinical variables representing known risk factors of DR (4; 5) such as HbA1c, were added as 8 covariates to logistic regression models to calculate adjusted odds ratios. Adjusted odds 9 ratios were also calculated for dominating trends that were identified from PCA, and for 10 major classes of diabetes medications. PCA was performed using SIMCA (Umetrics AB), all 11 other statistical tests were performed in the R environment. 12 with p<0.05 and a fold change greater than 1.2 or less than 0.8 were used as input. 27
13
Metabolite Identification
Canonical pathways were considered to be significantly enriched in the dataset if their FDR 28 were less than 0.2. 29 1 trehalose were purchased from Sigma-Aldrich. The compounds 2-deoxyribonic acid and 3,4-2 dihydroxybutyric acid were synthesized in-house and characterized by proton nuclear 3 magnetic resonance. Synthesis methods are described in the supplementary. Calibration 4 curves were constructed with standard solutions from 0.050 to 2.00 µg/mL. Plasma samples 5
were similarly derivatised and analysed by GC-MS. Besides the column length (28.5 m) and 6 detector voltage (1800 V), all other settings were the same as those used in for discovery 7 metabonomic profiling. Kruskal-Wallis tests (non-parametric ANOVA) were performed to 8 identify differences in plasma metabolite concentrations between groups. 9 10
Results
12
Sample Characteristics
13
The clinical characteristics of participants selected for discovery metabonomic profiling are 14 shown in Table 1 There were fourteen candidate metabolites identified from discovery metabonomic 5 profiling (p< 0.05, Mann-Whitney U test), and eleven met a q-value cut-off of 0.2 after 6 correction for multiple testing ( Table 2) . DR samples had decreased levels of 1,5-7 anhydroglucitol and increased levels of 1,5-gluconolactone; 2-deoxyribonic acid; 3,4-8 dihydroxybutyric acid; erythritol; gluconic acid; lactose/cellobiose; maltose/trehalose; 9 mannose; ribose and urea. A heatmap showing the relative peak area distribution of these 10 metabolites in DR cases and diabetic controls are shown in (Figure 1) . Analytical information 11 of all identified metabolite markers are provided in Table S1 . 12
The odds ratios of the metabolite markers in the basic logistic regression models and those 14 adjusted for systolic BP, HbA1c levels and diabetes duration are shown in Table 3 . While 15
HbA1c was a significant covariate for all metabolite markers (p<0.05 in likelihood-ratio test), 16 adjusted odds ratios for 1,5-anhydroglucitol; 1,5-gluconolactone; 2-deoxyribonic acid; 17 gluconic acid; lactose/cellobiose and urea remained significant ( Table 3) . Increased systolic 18 BP and diabetes duration are known risk factors of DR (4; 5) but these factors were not 19 significant covariates for any metabolite markers in our study ( Table 3) . The metabolite 20 markers 1,5-gluconolactone; 2-deoxyribonic acid; gluconic acid, lactose/cellobiose and urea 21 retained significant odds ratios when adjusted for systolic BP; HbA1c levels and diabetes 22 duration together ( Table 3) . Adjusted odds ratios for age, gender, BMI, diastolic BP, serum 23 creatinine, glucose, triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol, urine 24 albumin-to-creatinine ratio (ACR) and eGFR are shown in Table S2, Table S3 and Table S4 . 25 Age, gender, triglycerides, total cholesterol, LDL cholesterol and HDL cholesterol were not 26 significant covariates for any metabolite marker (Table S2, Table S3, Table S4 ). 27
28
The number of participants with prescriptions for each class of diabetes medications is 29 shown in Table S5 . Biguanides, sulphonylureas, thiazolindinediones and alpha glucosidase 30 inhibitors were not significant covariates for any metabolite marker, and insulin reduced the1
Validation of Metabolite Markers
2
The reproducibility of metabolite markers identified from discovery metabonomic profiling 3 was investigated in another set of samples selected from Singapore Indian Eye Study cohort. 4
To minimize the contributions of potentially confounding kidney disease and glycemic 5 control, participants with eGFR below 60 mL/min/1.73 m 2 were excluded, and diabetic 6 controls were matched to DR cases for HbA1c. Samples from non-diabetic individuals were 7 also analysed to establish reference ranges of these metabolites. The clinical characteristics 8 of participants selected for the validation set are summarized in Table S7 . 9 
10
In the validation set, DR cases showed increased plasma concentrations of 2-deoxyribonic 11 acid; 3,4-dihydroxybutyric acid, erythritol, gluconic acid and ribose when compared with 12 diabetic controls ( Table 4 ). In particular, diabetic controls also showed increased plasma 13 concentrations of gluconic acid when compared with non-diabetic individuals (Figure 2) . The 14 previously unresolved metabolite pairs, lactose and cellobiose, maltose and trehalose were 15 separated with the longer analytical column. Cellobiose was not detected in plasma samples. 
Metabolite Markers Complementary to Known Risk Factors
23
It is relevant to identify metabolite markers that are complementary to known risk factors 24 such as glycemic control (4; 5) to improve existing risk stratification in DR-free diabetic 25 patients and those with early stages of DR, (Figure 1) . A panel of eleven metabolite markers 26 was identified from discovery metabonomic profiling (Table 2) . These metabolite markers 27
are not only independent of HbA1c, but also remained statistically significant when adjusted 28 for known metabolic risk factors for DR and potentially confounding kidney disease. We 29 found that 1,5-gluconolactone, 2-deoxyribonic acid, gluconic acid and urea retain significant 30 odds ratios when adjusted for key clinical variables such systolic blood pressure, HbA1c,duration of diabetes, urine albumin-to-creatinine ratio, and glomerular filtration rate (Table  1 3, Table S4) sera have been identified as markers and predictors of type 2 diabetes, while decreased 6 levels of glycine were found to be correlated with diabetes (19; 21). Our results from 7 discovery metabonomic profiling showed no significant differences in the levels of these 8 amino acids between DR cases and diabetic controls. (Table S8 ). This contrast is likely due to 9 the definition and choice of the control group. In the aforementioned studies, control 10 samples were derived from healthy persons, while the controls in the discovery set were 11 sampled from diabetic persons who have potentially had pre-existing increased catabolism 12 of branched chain and aromatic amino acids. In addition, the majority of participants in our 13 study had been prescribed with diabetes-controlling medications ( Table 1) the view that arachidonic acid generally produces pro-inflammatory eicosanoids (38), no 21 significant differences linoleic acid and arachidonic acid levels were found between DR cases 22 and diabetic controls in the discovery set ( Table S8 ). The levels of arachidonic acid are likely 23 correlated to the use of anti-hypertensive medications than DR-status (39). This is 24 supported by the similar numbers of participants on anti-hypertensive medications among 25 the DR cases and diabetic control groups (27 and 24 respectively). 26 27 Omega-3 polyunsaturated fatty acids (PUFAs) are thought to aid in diabetes prevention but 28 meta-analyses on omega-3 fatty acids intake show heterogeneous results, stratified by 29 study locale (40). The omega-3 PUFAs, docosahexaenoic and eicosapentaenoic acid s were 30 detected on our platform, yet we did not find significant differences in these PUFAs 31 between the DR group and diabetic controls in the discovery set (Table S8) derivative of α-ketobutyrate, was previously identified as a marker (14; 21) and predictor 10 (44) for diabetes. The ketone body, 3-hydroxybutyric acid was identified as a marker for 11 impaired glucose tolerance (13) and type 2 diabetes (20; 21), and was also identified as a 12 marker for DR in Li et al.'s study (26) . No significant differences in the levels of 2-13 hydroxybutyric acid and 3-hydroxybutyric acid were found between DR cases and diabetic 14 controls in both the discovery and validation sets (Table S8) . DR cases and diabetic controls 15 showed increased levels of 2-hydroxybutyric acid than non-diabetic individuals, consistent 16 with a diagnosis of diabetes ( Figure S2 ). These findings, together with aforementioned 17 trends in amino acid levels suggest that plasma metabotype of DR is unique and not mere 18 extension of the plasma metabotype of diabetes. 19
20
There is accumulating evidence to support the contribution of altered gut microbiota to 21 obesity and diabetes (45) and gut microbiota-derived short-chain fatty acids (acetate, 22
propionate, butyrate) from gut microbiota have been identified as signaling molecules in 23 glucose and lipid metabolism (46). In our study, increased levels of 3,4-dihydroxybutyric acid 24 and 2-deoxyribonic acid in DR cases were identified using discovery metabonomic profiling 25 ( Figure 1, Table 2,) . Similar increases in the concentrations of 3,4-dihydroxybutyric acid and 26 2-deoxyribonic acid were also found in the validation set (Table 4) , though no significant 27 differences in the levels of these hydroxy fatty acids were found between diabetic controls 28 and non-diabetic individuals. These are no previous reports on the association of these 29 hydroxy fatty acids with diabetes or DR. At present, it is known that 3,4-dihydroxybutyric 30 acid is a urinary marker for succinate semialdehyde dehydrogenase deficiency (47) and thesugar moiety (48). These hydroxy fatty acids are not part of major metabolic pathways and 1 may be products of gut microbial metabolism on butyrate or other short-chain fatty acids. 2 Metabolic flux analysis of these 2-deoxyribonic acid and 3,4-dihydroxybutyric acid could be 3 performed to investigate their metabolic origins and their role in DR pathogenesis. 4
5
Metabonomic Profiling Identifies DR-associated pathways 6 Pathway mapping on MetaboAnalyst (37) showed that the pentose phosphate and 7 galactose metabolism pathways are significantly enriched (FDR<0.2) among the metabolite 8 markers identified from discovery metabonomic profiling. The pentose phosphate pathway 9 was identified with increased levels of 1,5-gluconolactone, gluconic acid and ribose; while 10 galactose metabolism was identified with lactose, mannose and myo-inositol (Table S9) . 11
Myo-inositol levels were increased among DR cases in the discovery set (1.25 fold) but did 12 not meet significance after correction for multiple testing. These results suggest that the 13 implications of selected metabolite classes (organic acids, polyols and sugars, oxidative 14 stress markers) in DR pathogenesis. 
